Beyond Air, Inc. - Common Stock (XAIR)
Frequently Asked Questions About Beyond Air, Inc. - Common Stock (XAIR)
Has Beyond Air received any regulatory approvals?
Beyond Air has received regulatory approvals for its LungFit device in certain markets. Specifically, it has obtained CE mark certification in Europe, allowing it to market and sell its product in the European Union. The company continues to work on securing additional approvals and clearances in other regions, including the U.S.
How can investors learn more about Beyond Air?
Investors can learn more about Beyond Air by visiting the company’s official website, where they can find detailed information on its products, clinical trials, financial reports, and press releases. Additionally, the company regularly updates its shareholders and the public through investor presentations and quarterly earnings calls.
How does Beyond Air differentiate itself from competitors?
Beyond Air differentiates itself through its unique approach to utilizing nitric oxide and other gases as therapeutic agents, setting it apart from traditional pharmaceutical companies. The company’s proprietary technologies and focus on non-invasive treatments offer innovative solutions that address critical healthcare challenges, particularly in respiratory disease management.
How does Beyond Air plan to grow?
Beyond Air plans to grow by advancing its clinical programs, expanding its product portfolio, and exploring partnerships and collaborations within the healthcare industry. The company is focused on increasing its market presence by addressing unmet medical needs and leveraging its innovative gas delivery technologies.
How does Beyond Air report its financial performance?
As a publicly traded company, Beyond Air is required to submit regular financial reports to the Securities and Exchange Commission (SEC). These reports include quarterly earnings reports, annual statements, and other filings that provide transparency regarding the company's financial performance, liabilities, and business activities.
Is Beyond Air publicly traded?
Yes, Beyond Air, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol XAIR. As a publicly traded company, it is subject to reporting requirements and regulations that provide transparency to its investors and stakeholders.
What are the company's future goals?
Beyond Air’s future goals include expanding the clinical applications of its technologies, increasing market penetration for its LungFit system, and seeking additional regulatory approvals for its products. The company aims to establish itself as a leader in the field of gaseous therapies for respiratory and other diseases.
What are the main therapeutic areas Beyond Air targets?
Beyond Air primarily targets respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company is also exploring applications of its nitric oxide technology for additional therapeutic areas, such as oncology and infectious diseases.
What challenges does Beyond Air face?
Like many clinical-stage companies, Beyond Air faces challenges such as navigating the regulatory approval process, securing funding for ongoing research and development, and successfully demonstrating the efficacy of its products in clinical trials. Additionally, competition within the biotechnology space can present hurdles in market entry and adoption.
What clinical trials is Beyond Air currently conducting?
Beyond Air is conducting several clinical trials to evaluate the efficacy and safety of its LungFit device in treating respiratory diseases. These trials encompass various stages of research, including early-stage safety studies and later-phase trials aimed at confirming the therapeutic benefits of nitric oxide in targeted patient populations.
What does Beyond Air, Inc. (Nasdaq: XAIR) do?
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company focused on the development of innovative therapies that utilize nitric oxide and other gases as therapeutic agents. The company's primary aim is to improve the treatment of respiratory diseases and various other conditions by leveraging its proprietary technology platform.
What is nitric oxide therapy?
Nitric oxide therapy is a medical treatment that involves the inhalation of nitric oxide gas to improve pulmonary blood flow and oxygen delivery. This therapy has been shown to have beneficial effects in treating various respiratory disorders by helping to reduce inflammation and facilitate better lung function.
What is the company's flagship product?
Beyond Air’s flagship product is the LungFit system, which delivers nitric oxide gas to patients with respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). This device aims to provide non-invasive therapy to patients, improving their overall respiratory health and enhancing their quality of life.
What is the company’s commitment to sustainability?
Beyond Air is committed to sustainability by implementing environmentally responsible practices in its operations and product development. The company recognizes the importance of minimizing its environmental footprint while advancing healthcare innovations and is continuously evaluating ways to enhance its sustainability efforts.
What is the significance of the company's ticker symbol XAIR?
The ticker symbol XAIR represents Beyond Air, Inc. on the Nasdaq stock market. Ticker symbols serve as a unique identifier for publicly traded companies, making it easier for investors and analysts to track stock performance and access financial information related to the company.
What partnerships does Beyond Air have?
Beyond Air has formed partnerships with various healthcare institutions, academic organizations, and research entities to advance its research and development efforts. These collaborations aim to enhance the clinical understanding of nitric oxide therapy and support the company’s ongoing clinical trials and product development.
When was Beyond Air, Inc. founded?
Beyond Air, Inc. was founded in 2011. Since its inception, the company has focused on developing cutting-edge therapies utilizing its unique platform, aimed at addressing significant unmet needs in the treatment of respiratory and other diseases.
Where is Beyond Air, Inc. headquartered?
Beyond Air, Inc. is headquartered in Garden City, New York. This location serves as the central hub for its research, development, and corporate operations, allowing the company to effectively manage its innovative projects and initiatives in the healthcare sector.
Who are the key executives at Beyond Air?
Beyond Air's key executives include a team of experienced professionals with backgrounds in medicine, biotechnology, and corporate strategy. The leadership team is committed to advancing the company’s mission and driving the development of innovative therapies that improve patient outcomes.
What is the current price of Beyond Air, Inc. - Common Stock?
The current price of Beyond Air, Inc. - Common Stock is 0.2454
When was Beyond Air, Inc. - Common Stock last traded?
The last trade of Beyond Air, Inc. - Common Stock was at 4:00 pm EDT on April 3rd, 2025